Biologic therapy and sarcoidosis: An immunological approach to treatment
Sarcoidosis is a multisystem granulomatous disease of unknown cause, characterised by the formation of non-caseating granulomas in various organs, most often the lungs and lymph nodes. The pathogenesis of sarcoidosis involves complex immunological processes, in which T lymphocytes, macrophages and cytokines play a key role. Biologic therapy, directed at specific components of the immune system, represents a promising approach to treating sarcoidosis, particularly in cases refractory to standard corticosteroid therapy.
More detailed immunological processes in sarcoidosis
In the pathogenesis of sarcoidosis, activation of CD4+ T lymphocytes leads to the formation of granulomas, collections of immune cells that damage the affected organs. Macrophages, transformed into epithelioid cells, are key components of granulomas. The key cytokines in this process are:
Tumour necrosis factor alpha (TNF-α): A key mediator of inflammation, it promotes granuloma formation and contributes to tissue damage. TNF-α acts by binding to TNF receptors (TNFR1 and TNFR2) on the cell surface, triggering signalling pathways that lead to the activation of NF-κB and AP-1, transcription factors that regulate the expression of pro-inflammatory genes.
Interleukin-1 (IL-1): A pro-inflammatory cytokine that enhances the immune response. IL-1 acts by binding to IL-1 receptors, activating signalling pathways similar to those of TNF-α.
Interleukin-6 (IL-6): Contributes to chronic inflammation and systemic manifestations of the disease. IL-6 acts by binding to the IL-6 receptor, activating the JAK/STAT signalling pathway.
Interferon gamma (IFN-γ): Plays a key role in the formation and maintenance of granulomas.
Biologic therapy: Targeted action on the immune system
Biologic medicines, such as TNF-α inhibitors (infliximab, adalimumab, certolizumab pegol and golimumab), target specific components of the immune system, blocking their action and reducing inflammation. This therapy is used when standard corticosteroid treatment is ineffective or causes intolerable side effects.
Infliximab (Remicade): A monoclonal antibody that binds to TNF-α, preventing it from binding to TNF receptors.
Adalimumab (Humira): A human monoclonal antibody that also blocks TNF-α.
Certolizumab pegol (Cimzia): A pegylated Fab fragment of a humanised monoclonal antibody.
Golimumab (Simponi): A human monoclonal antibody against TNF-alpha. In addition to anti-TNF therapy, other biologic medicines are being investigated, such as IL-1 inhibitors (anakinra) and IL-6 inhibitors (tocilizumab), but their effectiveness in treating sarcoidosis is still being studied.
The type of sarcoidosis that requires biologic therapy
Biologic therapy is most commonly used for refractory sarcoidosis, meaning cases in which standard corticosteroid treatment is not effective enough or causes serious side effects. In addition, biologic therapy may be used when sarcoidosis causes severe pulmonary, cardiac or neurological complications that do not respond to conventional therapies.
Contraindications to biologic therapy
Like any form of therapy, biologic medicines have certain contraindications:
Active infections: Biologic medicines, especially TNF-α inhibitors, may increase the risk of serious infections, so they must not be used in patients with active infections.
Severe immunodeficiencies: In patients with severe immunodeficiency conditions, such as HIV with a low CD4 cell count, biologic medicines may worsen immune function.
Heart failure: In patients with severe heart failure, the use of TNF-α inhibitors may worsen heart function.
Pregnancy and breastfeeding: Some biologic medicines, such as infliximab, are not recommended during pregnancy and breastfeeding because of potential risks to the fetus or newborn.
Route of administration and frequency of therapy
Biologic medicines are usually administered intravenously (IV) or subcutaneously (SC), depending on the specific medicine:
Infliximab (Remicade): Usually administered intravenously, initially with starting doses every 2 to 4 weeks. After the initial phase, doses may be reduced to every 8 weeks.
Adalimumab (Humira): Administered subcutaneously, usually every 2 weeks, and in some cases the frequency may be adjusted depending on the response to therapy.
Certolizumab pegol (Cimzia): Administered subcutaneously in the initial phase, usually every 2 to 4 weeks, and after the initial injections the dose may be reduced to every 4 weeks.
Golimumab (Simponi): Usually administered subcutaneously, with the initial dose every 4 weeks and the possibility of reducing the frequency according to the patient's response.
Adjustment of the frequency of biologic therapy depends on the patient's clinical response and side effects, with regular monitoring and assessment of the effectiveness and safety of treatment.
Effects on quality of life and immunity
Biologic therapy may significantly improve the quality of life of patients with sarcoidosis by reducing symptoms such as fatigue, dyspnoea and joint pain. In addition, it may lead to:
Reduced disease activity and regression of granulomas.
Improved function of the lungs and other affected organs.
A reduced need for corticosteroids and fewer of their side effects. However, biologic therapy may increase the risk of infections, so careful patient selection and regular monitoring are important.
Conclusion
Biologic therapy represents an important advance in the treatment of sarcoidosis, offering targeted action on immunological processes and improved patient quality of life. Although it carries certain risks, careful monitoring and an individualised approach can optimise the benefits of this therapy. Further research is needed to identify the optimal biologic medicines and treatment strategies for different forms of sarcoidosis.
Dino-Josip Ključarić
Infliximab
is a biologic medicine in the group of TNF blockers, medicines that prevent the action of a protein called TNFα (tumour necrosis factor alpha), which is involved in inflammatory processes.
The medicine is used for patients who tolerate corticosteroids poorly or have been taking them for too long.
Treatment of sarcoidosis with infliximab
Background/objectives:
Many patients with sarcoidosis cannot tolerate corticosteroids or alternative therapeutic agents because of side effects, or have disease that is resistant to these agents. We report our experience of using infliximab to treat such patients.
Methods:
A group of patients in whom traditional sarcoidosis therapy had failed, either because of drug failure or intolerable side effects, were prescribed infliximab. Their records were reviewed retrospectively.
Results:
Ten patients receiving infliximab were reviewed. Nine of the 10 patients reported symptomatic improvement with therapy, and all 10 showed objective evidence of improvement. One patient developed a drug reaction after several months of therapy, one patient developed oral candidiasis, and another developed angioimmunoblastic lymphoma. The corticosteroid dose was reduced in five of the six patients receiving corticosteroids at the time of infliximab therapy.
Conclusion:
Infliximab appears to be an effective and safe treatment for patients with refractory sarcoidosis, including manifestations such as lupus pernio, uveitis, hepatic sarcoidosis and neurosarcoidosis. Infliximab appears to be steroid-sparing. Patients receiving the medicine should be screened for latent tuberculosis and lymphoproliferative disorders.
Source: https://pubmed.ncbi.nlm.nih.gov/15764796/